TISIDB

Summary
Symbol	CTNNA1
Name	catenin (cadherin-associated protein), alpha 1, 102kDa
Aliases	CAP102; catenin (cadherin-associated protein), alpha 1 (102kD); alpha E-catenin; alpha-E-catenin; alpha-cate ......
Chromosomal Location	5q31.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Isoform 1: Cytoplasm, cytoskeleton. Cell junction, adherens junction. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Cell junction. Note=Found at cell-cell boundaries and probably at cell-matrix boundaries.; SUBCELLULAR LOCATION: Isoform 3: Cell membrane Peripheral membrane protein Cytoplasmic side
Domain	PF01044 Vinculin family
Function	Associates with the cytoplasmic domain of a variety of cadherins. The association of catenins to cadherins produces a complex which is linked to the actin filament network, and which seems to be of primary importance for cadherins cell-adhesion properties. Can associate with both E- and N-cadherins. Originally believed to be a stable component of E-cadherin/catenin adhesion complexes and to mediate the linkage of cadherins to the actin cytoskeleton at adherens junctions. In contrast, cortical actin was found to be much more dynamic than E-cadherin/catenin complexes and CTNNA1 was shown not to bind to F-actin when assembled in the complex suggesting a different linkage between actin and adherens junctions components. The homodimeric form may regulate actin filament assembly and inhibit actin branching by competing with the Arp2/3 complex for binding to actin filaments. May play a crucial role in cell differentiation.

> Gene Ontology [ TOP ]
Biological Process	GO:0001541 ovarian follicle development GO:0007015 actin filament organization GO:0007043 cell-cell junction assembly GO:0007163 establishment or maintenance of cell polarity GO:0007224 smoothened signaling pathway GO:0007229 integrin-mediated signaling pathway GO:0007405 neuroblast proliferation GO:0007406 negative regulation of neuroblast proliferation GO:0007548 sex differentiation GO:0007568 aging GO:0008406 gonad development GO:0008584 male gonad development GO:0008585 female gonad development GO:0008589 regulation of smoothened signaling pathway GO:0010721 negative regulation of cell development GO:0016264 gap junction assembly GO:0022602 ovulation cycle process GO:0031099 regeneration GO:0031102 neuron projection regeneration GO:0031103 axon regeneration GO:0034329 cell junction assembly GO:0034330 cell junction organization GO:0034332 adherens junction organization GO:0038034 signal transduction in absence of ligand GO:0040013 negative regulation of locomotion GO:0042475 odontogenesis of dentin-containing tooth GO:0042476 odontogenesis GO:0042692 muscle cell differentiation GO:0042698 ovulation cycle GO:0043297 apical junction assembly GO:0043627 response to estrogen GO:0045137 development of primary sexual characteristics GO:0045216 cell-cell junction organization GO:0045880 positive regulation of smoothened signaling pathway GO:0046545 development of primary female sexual characteristics GO:0046546 development of primary male sexual characteristics GO:0046660 female sex differentiation GO:0046661 male sex differentiation GO:0048511 rhythmic process GO:0048608 reproductive structure development GO:0048678 response to axon injury GO:0050768 negative regulation of neurogenesis GO:0051147 regulation of muscle cell differentiation GO:0051149 positive regulation of muscle cell differentiation GO:0051259 protein oligomerization GO:0051271 negative regulation of cellular component movement GO:0051291 protein heterooligomerization GO:0051961 negative regulation of nervous system development GO:0061351 neural precursor cell proliferation GO:0061458 reproductive system development GO:0061564 axon development GO:0071407 cellular response to organic cyclic compound GO:0071417 cellular response to organonitrogen compound GO:0071680 response to indole-3-methanol GO:0071681 cellular response to indole-3-methanol GO:0072089 stem cell proliferation GO:0072091 regulation of stem cell proliferation GO:0090136 epithelial cell-cell adhesion GO:0097191 extrinsic apoptotic signaling pathway GO:0097192 extrinsic apoptotic signaling pathway in absence of ligand GO:0097305 response to alcohol GO:0097306 cellular response to alcohol GO:1901099 negative regulation of signal transduction in absence of ligand GO:1902692 regulation of neuroblast proliferation GO:2000146 negative regulation of cell motility GO:2000177 regulation of neural precursor cell proliferation GO:2000178 negative regulation of neural precursor cell proliferation GO:2000647 negative regulation of stem cell proliferation GO:2001044 regulation of integrin-mediated signaling pathway GO:2001045 negative regulation of integrin-mediated signaling pathway GO:2001233 regulation of apoptotic signaling pathway GO:2001234 negative regulation of apoptotic signaling pathway GO:2001235 positive regulation of apoptotic signaling pathway GO:2001236 regulation of extrinsic apoptotic signaling pathway GO:2001237 negative regulation of extrinsic apoptotic signaling pathway GO:2001238 positive regulation of extrinsic apoptotic signaling pathway GO:2001239 regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001241 positive regulation of extrinsic apoptotic signaling pathway in absence of ligand
Molecular Function	GO:0003779 actin binding GO:0008013 beta-catenin binding GO:0017166 vinculin binding GO:0045295 gamma-catenin binding GO:0045296 cadherin binding GO:0050839 cell adhesion molecule binding GO:0051015 actin filament binding GO:0098631 protein binding involved in cell adhesion GO:0098632 protein binding involved in cell-cell adhesion GO:0098641 cadherin binding involved in cell-cell adhesion
Cellular Component	GO:0001669 acrosomal vesicle GO:0005901 caveola GO:0005913 cell-cell adherens junction GO:0005915 zonula adherens GO:0005924 cell-substrate adherens junction GO:0005925 focal adhesion GO:0014704 intercalated disc GO:0015629 actin cytoskeleton GO:0016342 catenin complex GO:0016600 flotillin complex GO:0019897 extrinsic component of plasma membrane GO:0019898 extrinsic component of membrane GO:0030027 lamellipodium GO:0030055 cell-substrate junction GO:0030141 secretory granule GO:0031252 cell leading edge GO:0043296 apical junction complex GO:0044291 cell-cell contact zone GO:0044853 plasma membrane raft GO:0045121 membrane raft GO:0097223 sperm part GO:0098589 membrane region GO:0098857 membrane microdomain GO:0099503 secretory vesicle

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04390 Hippo signaling pathway hsa04520 Adherens junction hsa04670 Leukocyte transendothelial migration
Reactome	R-HSA-418990: Adherens junctions interactions R-HSA-375170: CDO in myogenesis R-HSA-446728: Cell junction organization R-HSA-1500931: Cell-Cell communication R-HSA-421270: Cell-cell junction organization R-HSA-1266738: Developmental Biology R-HSA-525793: Myogenesis R-HSA-195258: RHO GTPase Effectors R-HSA-5626467: RHO GTPases activate IQGAPs R-HSA-162582: Signal Transduction R-HSA-194315: Signaling by Rho GTPases R-HSA-194138: Signaling by VEGF R-HSA-4420097: VEGFA-VEGFR2 Pathway R-HSA-5218920: VEGFR2 mediated vascular permeability

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04390 Hippo signaling pathway
hsa04520 Adherens junction
hsa04670 Leukocyte transendothelial migration

Reactome

R-HSA-418990: Adherens junctions interactions
R-HSA-375170: CDO in myogenesis
R-HSA-446728: Cell junction organization
R-HSA-1500931: Cell-Cell communication
R-HSA-421270: Cell-cell junction organization
R-HSA-1266738: Developmental Biology
R-HSA-525793: Myogenesis
R-HSA-195258: RHO GTPase Effectors
R-HSA-5626467: RHO GTPases activate IQGAPs
R-HSA-162582: Signal Transduction
R-HSA-194315: Signaling by Rho GTPases
R-HSA-194138: Signaling by VEGF
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218920: VEGFR2 mediated vascular permeability

Summary
Symbol	CTNNA1
Name	catenin (cadherin-associated protein), alpha 1, 102kDa
Aliases	CAP102; catenin (cadherin-associated protein), alpha 1 (102kD); alpha E-catenin; alpha-E-catenin; alpha-cate ......
Chromosomal Location	5q31.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CTNNA1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	CTNNA1
Name	catenin (cadherin-associated protein), alpha 1, 102kDa
Aliases	CAP102; catenin (cadherin-associated protein), alpha 1 (102kD); alpha E-catenin; alpha-E-catenin; alpha-cate ......
Chromosomal Location	5q31.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CTNNA1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.53	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CTNNA1
Name	catenin (cadherin-associated protein), alpha 1, 102kDa
Aliases	CAP102; catenin (cadherin-associated protein), alpha 1 (102kD); alpha E-catenin; alpha-E-catenin; alpha-cate ......
Chromosomal Location	5q31.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CTNNA1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.219	0.419
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.418	0.888
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.068	0.974
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.257	0.45
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.097	0.972
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.707	0.844
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.074	0.886
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.062	0.978
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.084	0.974
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.104	0.963
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.561	0.868
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.053	0.402

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CTNNA1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	7.7	-7.7	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	100	-100	0.143
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	CTNNA1
Name	catenin (cadherin-associated protein), alpha 1, 102kDa
Aliases	CAP102; catenin (cadherin-associated protein), alpha 1 (102kD); alpha E-catenin; alpha-E-catenin; alpha-cate ......
Chromosomal Location	5q31.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CTNNA1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CTNNA1
Name	catenin (cadherin-associated protein), alpha 1, 102kDa
Aliases	CAP102; catenin (cadherin-associated protein), alpha 1 (102kD); alpha E-catenin; alpha-E-catenin; alpha-cate ......
Chromosomal Location	5q31.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CTNNA1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CTNNA1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CTNNA1
Name	catenin (cadherin-associated protein), alpha 1, 102kDa
Aliases	CAP102; catenin (cadherin-associated protein), alpha 1 (102kD); alpha E-catenin; alpha-E-catenin; alpha-cate ......
Chromosomal Location	5q31.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CTNNA1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CTNNA1
Name	catenin (cadherin-associated protein), alpha 1, 102kDa
Aliases	CAP102; catenin (cadherin-associated protein), alpha 1 (102kD); alpha E-catenin; alpha-E-catenin; alpha-cate ......
Chromosomal Location	5q31.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CTNNA1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CTNNA1
Name	catenin (cadherin-associated protein), alpha 1, 102kDa
Aliases	CAP102; catenin (cadherin-associated protein), alpha 1 (102kD); alpha E-catenin; alpha-E-catenin; alpha-cate ......
Chromosomal Location	5q31.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CTNNA1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CTNNA1
Name	catenin (cadherin-associated protein), alpha 1, 102kDa
Aliases	CAP102; catenin (cadherin-associated protein), alpha 1 (102kD); alpha E-catenin; alpha-E-catenin; alpha-cate ......
Chromosomal Location	5q31.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CTNNA1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse CTNNA1